Market Place
Sourcing Support
ORIC Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
01 May 2026 //
GLOBENEWSWIRE
ORIC Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
03 Apr 2026 //
GLOBENEWSWIRE
ORIC Pharma Discloses Inducement Grants Under Nasdaq Rule LR
06 Mar 2026 //
GLOBENEWSWIRE
ORIC Pharma Discloses Inducement Grants Per Nasdaq Lr 5635(C)(4)
06 Feb 2026 //
GLOBENEWSWIRE
ORIC Pharma to Participate in Upcoming Investor Conferences
05 Feb 2026 //
GLOBENEWSWIRE
ORIC Pharma Outlines 2025 Operations And Future Milestones
12 Jan 2026 //
GLOBENEWSWIRE
ORIC Pharma To Present At 44th J.P. Morgan Healthcare Conference
06 Jan 2026 //
GLOBENEWSWIRE
ORIC Pharma Awards Inducement Grants Under Nasdaq Rule 5635(c)(4)
05 Dec 2025 //
GLOBENEWSWIRE
ORIC® Pharma Reveals Q3 2025 Financials, Clinical Updates
13 Nov 2025 //
GLOBENEWSWIRE
ORIC Pharma Discloses Inducement Grants Per Nasdaq LR 5635(C)(4)
07 Nov 2025 //
GLOBENEWSWIRE
ORIC Pharma To Join Investor Conferences
04 Nov 2025 //
GLOBENEWSWIRE
Oric Pharma Discloses Inducement Grants per Nasdaq LR 5635(c)(4)
05 Sep 2025 //
GLOBENEWSWIRE
Oric Pharmaceuticals to Present at Investor Conferences
27 Aug 2025 //
GLOBENEWSWIRE
ORIC® Pharmaceuticals names Kevin Brodbeck Chief Technical
18 Aug 2025 //
GLOBENEWSWIRE
Oric Cuts 20% of Staff to Focus on Clinical-Stage Drugs
13 Aug 2025 //
FIERCE BIOTECH
ORIC Pharmaceuticals` Q2 2025 Financial Results and Updates
12 Aug 2025 //
GLOBENEWSWIRE
ORIC Pharmaceuticals grants inducements under Nasdaq Listing
01 Aug 2025 //
GLOBENEWSWIRE
Oric Pharmaceuticals grants inducements under Nasdaq Listing
03 Jul 2025 //
GLOBENEWSWIRE
ORIC Pharma Reports Inducement Grants under Nasdaq LR 5635(c)(4)
06 Jun 2025 //
GLOBENEWSWIRE
Oric Pharmaceuticals Announces $125M Private Placement Financing
28 May 2025 //
GLOBENEWSWIRE
Oric Pharmaceuticals Reports Promising Data from ORIC-944 Trial
28 May 2025 //
GLOBENEWSWIRE
Oric Pharma To Present ORIC-944 Ph1b Data in mCRPC Combo
27 May 2025 //
GLOBENEWSWIRE
Oric Pharmaceuticals to Join Investor Conferences
27 May 2025 //
GLOBENEWSWIRE
Oric Pharmaceuticals Reports Q1 2025 Financial Results
05 May 2025 //
GLOBENEWSWIRE
ORIC Pharma Reports Inducement Grants under Nasdaq LR 5635(c)(4)
02 May 2025 //
GLOBENEWSWIRE
ORIC Pharma Reports Inducement Grants under Nasdaq LR 5635(c)(4)
04 Apr 2025 //
GLOBENEWSWIRE
ORIC Pharmaceuticals to Join Investor Conferences
31 Mar 2025 //
GLOBENEWSWIRE
ORIC Pharma Announces ORIC-944 Presentation At AACR 2025
25 Mar 2025 //
GLOBENEWSWIRE
ORIC Pharma Reports Inducement Grants under Nasdaq LR 5635(c)(4)
07 Mar 2025 //
GLOBENEWSWIRE
ORIC Pharma Announces Registrational Clinical Development
25 Feb 2025 //
GLOBENEWSWIRE
ORIC® Pharmaceuticals Reports Q4 and Full Year 2024 Results
18 Feb 2025 //
GLOBENEWSWIRE
ORIC Pharma Reports Inducement Grants under Nasdaq LR 5635(c)(4)
07 Feb 2025 //
GLOBENEWSWIRE
ORIC Pharma to Participate in Upcoming Investor Conferences
27 Jan 2025 //
GLOBENEWSWIRE
Oric® Shares Phase 1b Data For ORIC-944 And 2024 Highlights
13 Jan 2025 //
GLOBENEWSWIRE
ORIC® Pharma to Present at the 43rd Annual J.P. Morgan Conference
06 Jan 2025 //
GLOBENEWSWIRE
ORIC Pharma Reports Inducement Grants under Nasdaq LR 5635(c)(4)
03 Jan 2025 //
GLOBENEWSWIRE
ORIC Pharmaceuticals to Attend Investor Conferences
25 Nov 2024 //
GLOBENEWSWIRE
ORIC® Pharmaceuticals Reports Q3 2024 Financial Results & Updates
12 Nov 2024 //
GLOBENEWSWIRE
ORIC® Pharmaceuticals to Participate in Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
ORIC® Pharma Reports Inducement Grants under Nasdaq LR 5635(c)(4)
01 Nov 2024 //
GLOBENEWSWIRE
ORIC® Pharmaceuticals Presents Data on ORIC-114 at EORTC
23 Oct 2024 //
GLOBENEWSWIRE
ORIC Pharma Announces Presentation At EORTC On Molecular Target
09 Oct 2024 //
GLOBENEWSWIRE
ORIC Reports Inducement Grants under Nasdaq LR 5635(c)(4)
04 Oct 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Rule
06 Sep 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
26 Aug 2024 //
GLOBENEWSWIRE
ORIC Pharma Appoints Keith Lui As SVP Of Commercial And Medical Affairs
05 Aug 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule
02 Aug 2024 //
GLOBENEWSWIRE
ORIC Pharma Announces Collaborations For ORIC-944 Prostate Cancer Trial
16 Jul 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule
05 Jul 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals Reports Inducement Grants
07 Jun 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
29 May 2024 //
GLOBENEWSWIRE
ORIC Reports Q1 2024 Results, Operational Updates
06 May 2024 //
GLOBENEWSWIRE
ORIC Reports Nasdaq Listing Rule Inducement Grants
03 May 2024 //
GLOBENEWSWIRE
ORIC Doses First NSCLC Patients In ORIC-114 Phase 1b Expansion
15 Apr 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals Presents Data on Two Programs at the 2024 AACR
08 Apr 2024 //
GLOBENEWSWIRE
ORIC Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
04 Apr 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
11 Mar 2024 //
GLOBENEWSWIRE
ORIC Pharma to Present at the Leerink Partners Global Biopharma Conference
06 Mar 2024 //
GLOBENEWSWIRE
ORIC Pharmaceuticals Announces Multiple Presentations
05 Mar 2024 //
GLOBENEWSWIRE
